KB801 is Krystal Biotech's investigational redosable eye-drop gene therapy for neurotrophic keratitis. It is designed to enable sustained localized NGF expression in the front of the eye and potentially reduce high-frequency dosing burden associated with recombinant NGF drops. The program is in Phase 1/2 EMERALD-1 clinical development.
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.
Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06999733 |
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis |
RECRUITING | PHASE1/PHASE2 |
